CNR1 and cancer: In silico analyses showed that cannabinoid receptors were generally not prognostically significant, but are enriched (mostly at the RNA level where more data is available) in some cancer subtypes: CNR1 in glioma (Figure 2a), CNR2 in testicular cancer (Figure 2b), GPR119 in pancreatic cancer, where it is also a favourable prognostic factor (p < 0.001, Figure 2c [18]) and TRPV2 in melanoma, while it is an unfavourable prognostic factor in renal (p < 0.001, Figure 2d [19]) and testicular cancer (p < 0.001, Figure 2e [20]).